HURA TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (HURA) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.9% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About TuHURA Biosciences, Inc.
TuHURA Biosciences Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA Biosciences Inc., formerly known as Kintara Therapeutics Inc., is based in SAN DIEGO.
Sector
Healthcare
Industry
Biotechnology